Michael H. Davidson, Chief Executive Officer and Director of NewAmsterdam Pharma Co N.V. (NASDAQ:NAMS), filed a Form 4 on September 15, 2026, reporting the open-market purchase of 10,000 ordinary shares on September 14, 2026.

Key Highlights

  • Purchase transaction: Davidson acquired 10,000 ordinary shares of NewAmsterdam Pharma Co N.V. at $22.65 per share on September 14, 2026.
  • Direct beneficial ownership after transaction: 792,923 ordinary shares held directly, including 163,352 shares subject to unvested restricted stock unit awards.
  • Indirect holdings: 285,715 ordinary shares held indirectly through the Michael H. Davidson 2026 Grantor Retained Annuity Trust, of which Davidson is the sole annuitant and trustee.
  • Prior transfer noted: The filing reflects a prior transfer of 608,779 ordinary shares previously reported as indirectly beneficially owned and formerly held by Stichting Administratiekantoor EPNAP for the benefit of Davidson.
  • Transaction code: The acquisition is coded "P," indicating an open-market purchase.

Davidson's Share Purchase and Ownership Structure at NewAmsterdam Pharma

According to the filing, Michael H. Davidson, who serves as both Chief Executive Officer and a Director of NewAmsterdam Pharma Co N.V., purchased 10,000 ordinary shares on September 14, 2026, at a price of $22.65 per share. The transaction code "P" designates this as an open-market purchase. Following this acquisition, Davidson's direct beneficial ownership stands at 792,923 ordinary shares, which the filing notes includes 163,352 shares subject to restricted stock unit awards that remain subject to vesting.

The filing also discloses that Davidson indirectly beneficially owns 285,715 ordinary shares held by the Michael H. Davidson 2026 Grantor Retained Annuity Trust. According to the filing, Davidson is the sole annuitant and trustee of that trust. A separate footnote explains that the direct ownership figure reflects a prior transfer of 608,779 ordinary shares that had previously been reported as indirectly beneficially owned, formerly held of record by Stichting Administratiekantoor EPNAP for the benefit of Davidson.

NewAmsterdam Pharma Co N.V. is listed on NASDAQ under the ticker NAMS. The Form 4 was signed by Michael Marino as attorney-in-fact for Michael H. Davidson and submitted to the SEC on September 15, 2026. No derivative securities transactions were reported in this filing.

What Was Disclosed

The Form 4 filed September 15, 2026, discloses that CEO Michael H. Davidson of NewAmsterdam Pharma Co N.V. purchased 10,000 ordinary shares at $22.65 each on September 14, 2026, bringing his total direct holding to 792,923 shares, with an additional 285,715 shares held indirectly via a grantor retained annuity trust.